Vapotherm Inc.
107 Ridgely Avenue
Suite 9
Annapolis
Maryland
21401
United States
Tel: 410-974-9255
Fax: 410-974-9707
Website: http://www.vtherm.com/
Email: INFO@VTHERM.COM
46 articles with Vapotherm Inc.
-
Vapotherm Announces Pricing of Public Offering of Common Stock
8/1/2019
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of its public offering of 3,105,000 shares of its common stock at a price to the public of $14.50 per share
-
Vapotherm Announces Proposed Public Offering of Common Stock
7/30/2019
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock.
-
Vapotherm Reports Second Quarter 2019 Financial Results
7/29/2019
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the second quarter ended June 30, 2019.
-
Vapotherm to Report Second Quarter 2019 Financial Results
7/8/2019
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the second quarter of 2019 after the close of trading on Monday, July 29, 2019.
-
Vapotherm to Present at the William Blair 39th Annual Growth Stock Conference
5/24/2019
Vapotherm, Inc. announced that its management team will be presenting at the William Blair 39th Annual Growth Stock Conference on Wednesday, June 5th at the Loews Chicago Hotel in Chicago, Illinois.
-
Vapotherm to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
5/10/2019
Vapotherm, Inc. announced that its management team will be presenting at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15 at the Encore Hotel in Las Vegas, Nevada.
-
Vapotherm Reports First Quarter 2019 Financial Results
5/7/2019
Vapotherm, Inc. announced its financial and operating results for the first quarter ended March 31, 2019.
-
Vapotherm to Report First Quarter 2019 Financial Results
4/17/2019
Vapotherm, Inc. announced that it will release financial results for the first quarter of 2019 after the close of trading on Tuesday, May 7, 2019.
-
Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients
3/26/2019
More than one million patients with ADHF as a primary diagnosis are admitted to U.S. hospitals each year.
-
Vapotherm Reports Fourth Quarter and Fiscal Year 2018 Financial Results
3/12/2019
Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today fourth quarter and fiscal year 2018 financial results.
-
Vapotherm to Report Fourth Quarter and Fiscal Year 2018 Financial Results
2/20/2019
Vapotherm, Inc. announced that it will release financial results for the fourth quarter and fiscal year 2018 after the close of trading on Tuesday, March 12, 2019.
-
Vapotherm® Releases Next Generation of Capital Unit: Precision Flow Hi-VNI™ System
2/13/2019
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the release of the next generation of its capital unit: the Precision Flow Hi-VNI system.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
Vapotherm to be Added to the Russell 2000®, 3000® and Microcap® Indexes
12/24/2018
Vapotherm, Inc. announced today that it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after market close on December 21, 2018, as part of Russell’s quarterly addition of companies with recent initial public offerings.
-
Clinical Study Shows Vapotherm’s New IntellO2™ Module for Precision Flow® System Significantly Improves Maintenance of Premature Neonates in Target Oxygenation Range
12/4/2018
Vapotherm, Inc. today announced the publication of a key prospective, multi-center, controlled, order-randomized crossover trial.
-
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
-
Vapotherm Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/16/2018
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), today announced the closing of its initial public offering of 4,600,000 shares of common stock, at a price to the public of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 shares of common stock
-
Vapotherm Announces Pricing of Initial Public Offering
11/14/2018
Vapotherm, Inc. announced the pricing of its initial public offering of 4,000,000 shares of common stock at a price to the public of $14.00 per share.
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
-
U.S. Food and Drug Administration (FDA) Grants Vapotherm Hi-VNI® Technology System a New Product Category
10/9/2018
Vapotherm, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Vapotherm's latest version of the Precision Flow® product, the Precision Flow Hi-VNI™ system, a new product category and product code (QAV).